THe National Institutes of Health
(NIH), 10 biopharmaceutical
companies and several nonprofit
organisations have joined forces
to speed up validation of disease
targets.
The Accelerating Medicines
Partnership (AMP) will distinguish
biological disease targets most
likely to respond to new therapies
and characterise biomarkers.
The AMP partners, who include
GlaxoSmithKline, Pfizer and Sanofi,
will invest more than US$230m
over five years in the first projects,
focusing on Alzheimer’s Disease
and type 2 diabetes among others.
NIH said a critical element of the
partnership was the agreement
that data and analyses would be
made publicly available to the
biomedical community.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Feb 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.